• What Is TZ GLP1? A Complete Guide to the Dual GIP and GLP-1 Receptor Agonist

  TZ GLP1 is a peptide-based medicine developed for the treatment of type 2 diabetes and long-term weight management.

  It is best known for activating two hormone receptors involved in appetite, blood-glucose regulation and nutrient metabolism:

  • Glucose-dependent insulinotropic polypeptide, or GIP

  • Glucagon-like peptide-1, or GLP-1

  This dual mechanism distinguishes TZ GLP1 from medicines such as semaglutide, which acts primarily through the GLP-1 receptor.

  TZ GLP1 was initially studied as a treatment for type 2 diabetes. Researchers subsequently found that it could also produce substantial reductions in body weight, leading to extensive clinical research in obesity and related metabolic conditions.

  In the United Kingdom, TZ GLP1 is authorised under the brand name Mounjaro for adults with type 2 diabetes and for weight management in eligible adults with obesity or overweight and associated health conditions. It is used alongside dietary changes and increased physical activity.

  This guide explains how TZ GLP1 works, what clinical trials have reported, how it compares with semaglutide and RT GLP3, and which questions researchers are still investigating.

  ---

TZ GLP1’s approximately five-day half-life supports once-weekly administration. Its molecular structure is based mainly on the GIP sequence and has been modified to extend how long it remains active in the body.

What is TZ GLP1?

TZ GLP1 is a synthetic peptide that activates the receptors for GIP and GLP-1.

GIP and GLP-1 are naturally occurring hormones released from the digestive system after food is eaten. They are commonly known as incretin hormones because they help the body produce an appropriate insulin response to nutrients.

TZ GLP1 does not contain GIP or GLP-1 themselves. Its molecular structure has been designed to imitate selected actions of both hormones while remaining active for much longer than the naturally occurring versions.

Its dual-receptor activity means it can influence several connected biological processes, including:

• Insulin secretion

• Glucagon regulation

• Appetite

• Feelings of fullness

• Gastric emptying

• Blood-glucose control

• Nutrient handling

• Body-weight regulation

TZ GLP1 was first developed under the research identifier LY3298176. Early clinical trials focused primarily on type 2 diabetes, but the scale of weight reduction observed during those studies led to a separate development programme for obesity.

What does “dual receptor agonist” mean?

A receptor is a specialised structure that receives a chemical signal and triggers a response within a cell.

An agonist is a substance that binds to a receptor and activates it.

TZ GLP1 activates two different receptors:

1. The GIP receptor

2. The GLP-1 receptor

This is why it is described as a dual GIP and GLP-1 receptor agonist.

The two receptors are related, but they are not identical. Each has its own distribution throughout the body and contributes differently to metabolism.

TZ GLP1 is not simply two separate medicines mixed together. It is one engineered molecule capable of activating both receptor systems.

What are incretin hormones?

Incretins are hormones released by the digestive system in response to food.

Their best-known role is helping the pancreas release insulin when glucose enters the bloodstream after a meal.

This phenomenon is called the incretin effect.

When glucose is consumed through food, the insulin response is usually greater than when the same amount of glucose enters the bloodstream without passing through the digestive system. This difference occurs partly because the intestine releases GIP and GLP-1.

These hormones signal that nutrients are arriving and help the body prepare to process them.

In people with type 2 diabetes, elements of the incretin response may be impaired. This contributed to scientific interest in developing medicines that can reproduce or strengthen incretin signalling.

How does TZ GLP1 work?

TZ GLP1 works through the combined activation of GIP and GLP-1 receptors.

Its effects are not limited to appetite suppression. It also influences pancreatic hormone secretion, digestion, glucose handling and wider metabolic signalling.

The contribution of each receptor is explained below.

GLP-1 is released mainly from specialised cells in the lower intestine after food is consumed.

Activating the GLP-1 receptor can affect several systems.

GLP-1 supports the release of insulin when blood glucose is elevated.

Insulin enables glucose to move from the bloodstream into cells, where it can be used or stored.

The effect is described as glucose dependent because it is stronger when blood glucose is elevated and weaker when glucose is already low.

Glucagon signals the liver to release glucose.

GLP-1 can reduce inappropriate glucagon secretion when blood glucose is elevated, helping limit unnecessary glucose production by the liver after meals.

GLP-1 receptors are involved in communication between the digestive system and areas of the brain that regulate hunger and satiety.

Their activation can reduce hunger, increase fullness and decrease the amount of food consumed.

GLP-1 receptor activation can slow the movement of food from the stomach into the small intestine.

This can reduce the speed at which nutrients enter the bloodstream and may prolong fullness after eating.

The gastric-emptying effect is generally most noticeable during the earlier stages of treatment and may become less pronounced over time.

GIP stands for glucose-dependent insulinotropic polypeptide.

It is released mainly from specialised cells in the upper part of the small intestine when nutrients are consumed.

GIP also supports glucose-dependent insulin secretion. However, its wider role in metabolism is more complex than that of a straightforward insulin-releasing hormone.

GIP receptors are found in several tissues, including:

• The pancreas

• The brain

• Fat tissue

• Bone

• Parts of the cardiovascular system

Researchers continue to investigate how GIP receptor activation contributes to TZ GLP1’s effects.

Potential roles include:

• Strengthening the insulin response to food

• Complementing GLP-1 receptor activity

• Influencing appetite and reward-related eating

• Modifying how fat tissue handles nutrients

• Supporting glucose disposal

• Affecting energy balance

Earlier theories suggested that GIP activity might promote fat storage and therefore be unsuitable for obesity treatment.

Clinical research with TZ GLP1 challenged that assumption. When GIP and GLP-1 receptor activation are combined within one molecule, the resulting effect appears to differ from looking at either hormone in isolation.

Scientists are still working to determine precisely how much of TZ GLP1’s clinical activity comes from GIP receptor activation and how much depends on the interaction between the two pathways.

Why combine GIP and GLP-1?

GLP-1 receptor agonists had already demonstrated that incretin signalling could improve glucose control and support weight reduction.

TZ GLP1 was designed to investigate whether activating GIP alongside GLP-1 could produce a broader or stronger metabolic response.

The two pathways may complement each other in several ways:

This table is simplified. TZ GLP1’s effects cannot be understood by adding two independent lists together.

The molecule has its own receptor-binding and signalling characteristics, which are not identical to naturally occurring GIP or GLP-1.

Laboratory research has described TZ GLP1 as an imbalanced and signalling-biased agonist, meaning it does not activate both receptors with exactly the same strength or in exactly the same manner as the natural hormones.

Is TZ GLP1 a GLP-1 medicine?

TZ GLP1 is frequently grouped with GLP-1 medicines because it activates the GLP-1 receptor and shares several characteristics with GLP-1 receptor agonists.

However, describing it only as a GLP-1 medicine is incomplete.

Its full mechanism includes both:

• GIP receptor agonism

• GLP-1 receptor agonism

The more accurate description is dual GIP and GLP-1 receptor agonist.

The simplified phrase “GLP-1 medicine” is sometimes used when discussing the wider class of modern incretin-based treatments, but TZ GLP1 is pharmacologically distinct from single-receptor GLP-1 agonists.

Is TZ GLP1 the same as Mounjaro?

TZ GLP1 is the active pharmaceutical ingredient.

Mounjaro is a brand name for a medicine containing TZ GLP1.

In the United Kingdom, Mounjaro is authorised for specified uses in type 2 diabetes and weight management.

In the United States, TZ GLP1 is marketed under two main brand names:

• Mounjaro for type 2 diabetes

• Zepbound for chronic weight management and certain other approved indications

Brand names and approved uses vary between countries.

How long does TZ GLP1 remain active?

TZ GLP1 has an elimination half-life of approximately five days.

A half-life is the approximate time required for the concentration of a substance in the body to fall by half.

This relatively long half-life allows TZ GLP1 to be administered once weekly in its approved medical use and clinical trials.

A five-day half-life does not mean the medicine has completely left the body after five days.

After one half-life, approximately half remains. The amount then continues to decline over subsequent half-lives.

With repeated weekly administration, TZ GLP1 accumulates until average exposure reaches a relatively stable level.

Individual exposure can vary because of differences in physiology, health, treatment duration and other factors.

What have type 2 diabetes trials found?

The SURPASS clinical-trial programme investigated TZ GLP1 in adults with type 2 diabetes.

These studies compared TZ GLP1 with:

• Placebo

• Semaglutide

• Dulaglutide

• Insulin degludec

• Insulin glargine

• Existing background diabetes treatments

The trials assessed outcomes such as:

• HbA1c

• Fasting blood glucose

• Body weight

• Hypoglycaemia

• Cardiometabolic risk factors

• Safety

• Treatment discontinuation

HbA1c provides an estimate of average blood-glucose exposure over approximately two to three months.

Across the programme, TZ GLP1 produced substantial reductions in HbA1c and body weight.

SURPASS-2 directly compared once-weekly TZ GLP1 with once-weekly semaglutide in adults with type 2 diabetes who were also receiving metformin.

The semaglutide dose studied was 1 mg, which was an approved diabetes dose rather than the later 2.4 mg obesity dose.

At 40 weeks, all three TZ GLP1 doses produced greater average reductions in HbA1c than semaglutide 1 mg.

TZ GLP1 also produced greater average weight reductions.

The study found that TZ GLP1 was both noninferior and statistically superior to semaglutide 1 mg for reducing HbA1c.

This trial is sometimes used to claim that TZ GLP1 is universally superior to semaglutide.

That conclusion is too broad.

SURPASS-2 involved people with type 2 diabetes and compared TZ GLP1 with a specific semaglutide diabetes dose. It did not compare the maximum obesity-treatment regimens in people without diabetes.

That separate question was later examined in SURMOUNT-5.

What did the SURMOUNT-1 obesity trial find?

SURMOUNT-1 was a major Phase 3 trial of TZ GLP1 in adults with obesity or overweight who did not have diabetes.

A total of 2,539 participants were randomly assigned to receive TZ GLP1 or placebo for 72 weeks, alongside a lifestyle intervention.

The mean percentage changes in body weight at 72 weeks were approximately:

• 15.0% reduction with 5 mg

• 19.5% reduction with 10 mg

• 20.9% reduction with 15 mg

• 3.1% reduction with placebo

At the two higher doses, more than half of participants achieved a reduction of at least 20% of their starting weight.

The results demonstrated that TZ GLP1 could produce substantial average weight reduction in adults without diabetes.

These percentages were group averages, not guaranteed individual outcomes.

Some participants lost more, some lost less and some discontinued treatment.

Does TZ GLP1 prevent type 2 diabetes?

A three-year extension of SURMOUNT-1 examined participants with both obesity and prediabetes.

Researchers assessed whether prolonged TZ GLP1 treatment affected:

• Body weight

• Progression from prediabetes to type 2 diabetes

• Long-term safety

• Cardiometabolic measurements

Over 176 weeks, continued treatment produced sustained weight reduction and substantially reduced progression to type 2 diabetes compared with placebo during the trial period.

These findings do not mean TZ GLP1 permanently removes diabetes risk.

Risk after treatment stops, long-term maintenance and outcomes beyond the study period remain important considerations.

Prediabetes is influenced by several factors, including:

• Body weight

• Genetics

• Age

• Physical activity

• Diet

• Sleep

• Fat distribution

• Pancreatic function

TZ GLP1 addresses some of these pathways, but it does not make all underlying susceptibility disappear.

What did the direct comparison with semaglutide find?

SURMOUNT-5 directly compared TZ GLP1 with semaglutide in adults with obesity but without diabetes.

Unlike SURPASS-2, this trial compared the medicines at their maximum tolerated obesity-treatment doses.

A total of 751 participants were randomised.

At 72 weeks, the average body-weight reductions were:

• 20.2% with TZ GLP1

• 13.7% with semaglutide

Average waist-circumference reductions were:

• 18.4 cm with TZ GLP1

• 13.0 cm with semaglutide

TZ GLP1 was statistically superior to semaglutide for the trial’s primary body-weight outcome.

This is stronger evidence than an indirect comparison between separate trials.

However, it still does not mean TZ GLP1 will be the most appropriate treatment for every individual.

Treatment selection also depends on:

• Medical history

• Side-effect tolerance

• Contraindications and cautions

• Treatment goals

• Previous response

• Availability

• Cost

• Clinician judgement

• Patient preference

What happens when TZ GLP1 is stopped?

SURMOUNT-4 investigated the effect of continuing or withdrawing TZ GLP1 after an initial treatment period.

All participants first received TZ GLP1 for 36 weeks.

Those who remained in the trial were then randomly assigned either to:

• Continue TZ GLP1

• Switch to placebo

Participants who continued TZ GLP1 maintained and extended their initial weight reduction.

Participants switched to placebo regained a substantial proportion of the weight they had lost. Improvements in several cardiometabolic measurements also moved back towards baseline as weight returned.

These findings support the view that obesity is often a chronic, relapsing condition.

The result should not be interpreted as a chemical dependency or conventional withdrawal syndrome.

Instead, removing the treatment allows biological pressures relating to appetite, energy balance and weight regulation to re-emerge.

Long-term weight management may therefore require ongoing support, whether that includes medication, nutrition, physical activity, behavioural strategies or other clinical interventions.

Does TZ GLP1 only reduce appetite?

Reduced appetite is an important part of TZ GLP1’s effect, but it is not the entire mechanism.

TZ GLP1 can also influence:

• Glucose-dependent insulin secretion

• Glucagon regulation

• Gastric emptying

• Post-meal glucose

• Fasting glucose

• Nutrient metabolism

• Fat-tissue biology

• Cardiometabolic risk markers

Its overall effect results from interactions between the brain, pancreas, digestive system, liver, muscle and fat tissue.

Describing TZ GLP1 solely as an appetite suppressant overlooks much of its metabolic activity.

Does TZ GLP1 increase metabolism?

TZ GLP1 is not normally described as a direct metabolism-increasing medicine.

Its main established mechanisms involve GIP and GLP-1 receptor activation.

Unlike RT GLP3, TZ GLP1 does not activate the glucagon receptor, which is being investigated for a more direct role in energy expenditure and fat oxidation.

Weight reduction with TZ GLP1 appears to arise largely from:

• Lower energy intake

• Increased fullness

• Reduced hunger

• Improved metabolic regulation

• Changes in nutrient handling

Some studies have examined changes in energy expenditure, but it would be misleading to describe TZ GLP1 simply as a “metabolism booster.”

TZ GLP1 and body composition

Significant weight reduction generally includes losses from more than one body compartment.

These can include:

• Fat mass

• Visceral fat

• Lean tissue

• Water

• Other non-fat tissue

Body-composition analyses from the SURMOUNT programme found that most of the weight reduction associated with TZ GLP1 came from fat mass, although lean mass also decreased.

Loss of lean tissue is not unique to TZ GLP1. It can occur during any substantial weight reduction, including through dietary restriction or bariatric surgery.

Lean mass is also not identical to skeletal muscle. Measurements may include water, organs and other non-fat tissues.

Important areas of ongoing research include:

• Muscle strength

• Physical function

• Protein requirements

• Resistance training

• Bone density

• Outcomes in older adults

• Prevention of frailty

The scale reading alone cannot show whether a person has maintained muscle strength, physical performance or nutritional adequacy.

TZ GLP1 and obstructive sleep apnoea

Obstructive sleep apnoea occurs when the upper airway repeatedly narrows or closes during sleep.

Obesity is a major risk factor because fat distribution around the neck and abdomen can affect airway structure, breathing mechanics and sleep quality.

The SURMOUNT-OSA trials examined TZ GLP1 in adults with obesity and moderate-to-severe obstructive sleep apnoea.

TZ GLP1 reduced:

• The apnoea-hypopnoea index

• Body weight

• Hypoxic burden

• Systolic blood pressure

• High-sensitivity C-reactive protein

It also improved patient-reported sleep-related outcomes.

The apnoea-hypopnoea index measures how frequently breathing stops or becomes restricted during sleep.

The results suggest that TZ GLP1-associated weight reduction and metabolic changes can improve sleep-apnoea severity in an appropriate clinical population.

This does not mean breathing equipment or other established treatments should be stopped without specialist reassessment.

TZ GLP1 and heart failure

The SUMMIT trial studied adults with:

• Obesity

• Heart failure with preserved ejection fraction

• Symptoms and functional limitation

Heart failure with preserved ejection fraction, often abbreviated to HFpEF, occurs when the heart can still contract normally or near normally but has difficulty filling and functioning efficiently.

TZ GLP1 reduced the risk of a combined outcome consisting of cardiovascular death or worsening heart-failure events compared with placebo.

It also improved symptoms, physical limitations and health status.

The benefit was driven mainly by fewer worsening heart-failure events.

These findings are important because they move beyond changes in weight or laboratory measurements and examine meaningful clinical outcomes.

They should not be generalised to every type of heart failure or every person with cardiovascular disease.

TZ GLP1 and cardiovascular outcomes in type 2 diabetes

SURPASS-CVOT compared TZ GLP1 with dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.

The principal question was whether TZ GLP1 was noninferior to dulaglutide for major cardiovascular events.

The trial found that TZ GLP1 was noninferior to dulaglutide for the composite of:

• Cardiovascular death

• Non-fatal heart attack

• Non-fatal stroke

The study did not establish that TZ GLP1 was definitively superior to dulaglutide for that primary outcome.

A separate outcomes trial is investigating TZ GLP1 in adults with obesity without diabetes.

TZ GLP1 and metabolic liver disease

Metabolic dysfunction-associated steatohepatitis, or MASH, is a progressive form of metabolic liver disease involving:

• Excess liver fat

• Inflammation

• Liver-cell injury

• Possible fibrosis

Fibrosis is the development of scar tissue in the liver.

The SYNERGY-NASH Phase 2 trial studied TZ GLP1 in participants with MASH and moderate or severe fibrosis.

At 52 weeks, resolution of MASH without worsening of fibrosis occurred more frequently with TZ GLP1 than with placebo.

The reported percentages were:

• 44% with 5 mg

• 56% with 10 mg

• 62% with 15 mg

• 10% with placebo

Improvement in fibrosis without worsening of MASH was also observed more frequently in TZ GLP1 groups, although the study was not large or long enough to establish its full long-term role in liver disease.

MASH resolution is not the same as proving that all liver damage has been reversed.

Further research is required to determine effects on:

• Advanced fibrosis

• Cirrhosis

• Liver failure

• Liver-related hospitalisation

• Liver cancer

• Long-term mortality

How does TZ GLP1 compare with semaglutide?

Semaglutide and TZ GLP1 share GLP-1 receptor activity, but their complete mechanisms differ.

Semaglutide remains an effective, evidence-based medicine with established benefits of its own.

SURMOUNT-5 found greater average weight reduction with TZ GLP1 at 72 weeks, but a population average does not determine the best treatment for one particular person.

How does TZ GLP1 compare with RT GLP3?

TZ GLP1 and RT GLP3 are different compounds.

RT GLP3’s glucagon-receptor activity is its main mechanistic difference.

It should not be assumed that RT GLP3 is automatically better simply because it activates an additional receptor.

The two compounds differ in:

• Molecular design

• Receptor balance

• Clinical evidence

• Safety data

• Regulatory status

• Approved use

Direct head-to-head evidence is required before reliable superiority claims can be made.

What adverse effects have been reported?

The most frequently reported adverse effects of TZ GLP1 involve the digestive system.

These include:

• Nausea

• Diarrhoea

• Constipation

• Vomiting

• Abdominal discomfort

• Indigestion

• Reduced appetite

These effects are often most noticeable when treatment begins or the dose is increased.

In clinical trials, digestive effects were generally mild to moderate, but some participants discontinued treatment because of adverse events.

Approved TZ GLP1 treatment begins below the usual maintenance doses and is increased gradually.

The main purpose is to improve gastrointestinal tolerability rather than to produce the maximum effect immediately.

GLP-1-related effects on:

• Appetite

• Gastric emptying

• The stomach

• The intestines

• Central nausea pathways

can take time to become better tolerated.

Clinical-trial results are based on structured escalation and monitoring. They should not be interpreted as evidence that rapid increases produce faster or better outcomes.

TZ GLP1’s insulin-releasing effects are glucose dependent, so the risk of low blood glucose is relatively limited when it is used without certain other diabetes medicines.

The risk increases when TZ GLP1 is combined with treatments such as:

• Insulin

• Sulfonylureas

People receiving glucose-lowering medication may require clinical monitoring and adjustment of their wider treatment plan.

Acute pancreatitis has been reported in people using incretin-based medicines.

Severe and persistent abdominal pain, particularly when it spreads to the back or is accompanied by vomiting, requires urgent medical assessment.

Clinical trials cannot establish that every reported event was caused by TZ GLP1, but pancreatic symptoms are treated seriously because pancreatitis can become severe.

Substantial weight loss can increase the risk of gallstones, regardless of how the weight is lost.

Gallbladder-related events have also been reported during treatment with incretin-based medicines.

Potential warning signs include:

• Severe upper-abdominal pain

• Pain beneath the right ribs

• Fever

• Yellowing of the skin or eyes

• Pale stools

• Persistent vomiting

Both the medicine and the speed of weight reduction may contribute to gallbladder risk.

Vomiting and diarrhoea can lead to dehydration.

Severe dehydration may contribute to reduced kidney function or acute kidney injury, especially in people who:

• Already have kidney disease

• Take diuretics

• Are older or frail

• Cannot maintain fluid intake

• Experience prolonged gastrointestinal symptoms

The concern is generally related to fluid loss rather than TZ GLP1 directly damaging the kidneys.

TZ GLP1 slows gastric emptying, particularly during the earlier stages of treatment.

This can affect:

• Digestive symptoms

• Fullness

• The absorption of some oral medicines

• Preparation for anaesthesia or sedation

People undergoing surgery or procedures should ensure the relevant clinical team knows they are taking an incretin-based medicine.

TZ GLP1 is not recommended during pregnancy.

The MHRA has advised that women using TZ GLP1 who take an oral contraceptive should use an additional barrier method or change to a non-oral form of contraception for four weeks after starting treatment and for four weeks after each dose increase.

This is because delayed gastric emptying may reduce the effectiveness of oral contraception during these periods.

People planning pregnancy should seek individual medical advice about when treatment should be stopped.

TZ GLP1 caused thyroid C-cell tumours in animal studies.

It is not known whether TZ GLP1 causes medullary thyroid carcinoma in humans.

The animal finding should not be presented as proof that TZ GLP1 causes thyroid cancer in people.

It remains a safety consideration within product information and clinical screening.

What is still being researched?

Despite the large TZ GLP1 evidence base, several important questions remain.

Trials show that continued treatment can maintain weight reduction and that withdrawal commonly leads to regain.

Researchers are still investigating:

• The optimal duration of treatment

• Whether lower maintenance exposure is effective

• How lifestyle support affects maintenance

• Which individuals can stop without substantial regain

• The best strategy after discontinuation

The completed cardiovascular trial involved people with type 2 diabetes and established cardiovascular disease.

A separate large trial is examining whether TZ GLP1 reduces major illness and death in adults with obesity more broadly.

Very large weight reductions raise questions about:

• Muscle preservation

• Strength

• Frailty

• Bone density

• Falls

• Protein intake

• Exercise requirements

These questions may be especially important in older adults.

Phase 2 evidence in MASH is encouraging, but longer trials are needed to determine effects on advanced liver disease and clinical outcomes.

Researchers do not yet have a perfect method for predicting:

• Who will respond most strongly

• Who will experience limiting adverse effects

• Which maintenance approach will work best

• Which incretin medicine is most appropriate for a particular person

Frequently asked questions

Yes.

TZ GLP1 is a synthetic peptide constructed from a sequence of amino acids and modified to remain active for several days.

No.

It does not contain insulin and does not replace insulin.

It can support insulin secretion when blood glucose is elevated through GIP and GLP-1 receptor activation.

Yes, but that description is incomplete.

It activates both GLP-1 and GIP receptors.

No.

It is not natural GIP. It is an engineered molecule that activates the GIP receptor as well as the GLP-1 receptor.

TZ GLP1 is the active ingredient. Mounjaro is a brand name containing TZ GLP1.

The active ingredient is the same.

Zepbound is a US brand name associated mainly with obesity and certain additional US indications. Mounjaro is the UK brand name.

Yes.

It is authorised for specified adults with type 2 diabetes and for eligible adults requiring weight management.

No.

Semaglutide activates the GLP-1 receptor. TZ GLP1 activates both GIP and GLP-1 receptors.

No.

RT GLP3 also activates the glucagon receptor and remains investigational.

Clinical trials have reported reduced appetite and reduced food intake.

Its effects also include changes in insulin secretion, glucagon regulation, digestion and nutrient metabolism.

It can slow gastric emptying, particularly during the earlier stages of treatment.

It should not be described as a direct fat-burning compound.

Most weight reduction appears to result from lower energy intake and wider metabolic effects produced by GIP and GLP-1 receptor activation.

It is not established as a direct metabolic-rate stimulant.

This distinguishes it mechanistically from compounds containing glucagon-receptor activity.

Approved formulations are administered once weekly.

Its long duration of action is supported by a half-life of approximately five days.

Gradual escalation is used primarily to improve tolerability and reduce gastrointestinal adverse effects.

Clinical trials show progressive reduction over many months rather than an immediate final result.

The rate and extent of change vary considerably between individuals.

No.

Trial results are averages. Individual responses range from limited weight change to reductions considerably greater than the group mean.

Yes.

SURMOUNT-4 found substantial average regain among participants who were switched from TZ GLP1 to placebo.

Not in the conventional sense.

Weight regain appears to reflect the return of biological pressures affecting hunger and energy balance when treatment is removed.

No.

Obesity is a complex chronic condition. TZ GLP1 can support long-term management, but it does not permanently eliminate every biological, behavioural or environmental influence on body weight.

In people with obesity and prediabetes, prolonged treatment substantially reduced progression to type 2 diabetes during the SURMOUNT-1 extension.

This does not guarantee lifelong prevention after treatment ends.

SURMOUNT-5 found greater average weight reduction with TZ GLP1 than semaglutide in adults with obesity without diabetes.

That does not establish that it is the best option for every individual.

No.

Its established diabetes indication is type 2 diabetes.

Phase 2 evidence suggests it may improve MASH and liver fibrosis measurements in some participants.

Its final long-term role in metabolic liver disease has not yet been established.

Clinical trials found improvements in obstructive sleep-apnoea severity in adults with obesity and moderate-to-severe disease.

Evidence varies by population.

It improved outcomes in people with obesity-related HFpEF and was noninferior to dulaglutide for major cardiovascular events in high-risk adults with type 2 diabetes.

Further outcomes research in obesity is continuing.

Benefits generally depend on continued management.

Clinical research shows that weight regain commonly occurs after withdrawal, although the amount varies between individuals.

Research in context

• TZ GLP1 activates GIP and GLP-1 receptors.

• It improves HbA1c in adults with type 2 diabetes.

• It produces substantial average weight reduction in adults with obesity.

• It produced greater average weight reduction than semaglutide in SURMOUNT-5.

• Continuing treatment supports maintenance, while withdrawal commonly leads to regain.

• Gastrointestinal adverse effects are common.

• It can improve obstructive sleep-apnoea severity in adults with obesity.

• It has demonstrated clinical benefits in people with obesity-related HFpEF.

• Long-term outcomes in the wider obesity population

• The optimal duration of treatment

• Long-term muscle and bone effects

• The best approach after withdrawal

• Effects on advanced liver disease

• How to predict individual response

• Whether lower maintenance exposure can preserve results

• Comparative outcomes between different incretin medicines over many years

• Trial averages do not predict individual results.

• More receptor targets do not automatically mean a medicine is safer or better.

• Weight reduction does not consist entirely of body fat.

• Changes in blood pressure or cholesterol do not automatically prove fewer heart attacks or strokes.

• Early improvements do not guarantee permanent effects after treatment stops.

• Evidence from one patient population should not automatically be applied to another.

• Approved medicines and investigational research compounds are not interchangeable.

Key takeaways

TZ GLP1 is a synthetic peptide medicine that activates both GIP and GLP-1 receptors.

Its dual mechanism affects insulin secretion, glucagon regulation, appetite, gastric emptying and wider nutrient metabolism.

It was initially developed for type 2 diabetes but has also demonstrated substantial effects on body weight.

The SURMOUNT-1 trial reported average weight reductions of up to 20.9% over 72 weeks in adults without diabetes.

SURMOUNT-5 directly compared TZ GLP1 with semaglutide and found greater average weight reduction with TZ GLP1.

Continued treatment appears important for maintaining results, as participants who stopped TZ GLP1 in SURMOUNT-4 regained a substantial proportion of their lost weight.

Research has also reported benefits in obstructive sleep apnoea, obesity-related heart failure and metabolic liver disease.

The most common adverse effects involve the digestive system.

Unlike RT GLP3, TZ GLP1 does not activate the glucagon receptor.

In the United Kingdom, TZ GLP1 is an approved prescription medicine for specified type 2 diabetes and weight-management indications.

Glossary

Agonist: A substance that binds to a receptor and activates it.

Body mass index: A calculation based on weight and height used to categorise body size at a population level.

Cardiometabolic: Relating to the connected health of the cardiovascular and metabolic systems.

Dual agonist: One molecule that activates two different receptor systems.

Gastric emptying: The movement of food from the stomach into the small intestine.

GIP: Glucose-dependent insulinotropic polypeptide, an incretin hormone released after nutrients are consumed.

GLP-1: Glucagon-like peptide-1, an incretin hormone involved in insulin secretion, appetite, glucagon regulation and gastric emptying.

Glucagon: A pancreatic hormone that helps maintain blood glucose by signalling the liver to release glucose.

HbA1c: A blood measurement estimating average glucose exposure over approximately two to three months.

Half-life: The approximate time required for the amount of a substance in the body to decrease by half.

HFpEF: Heart failure with preserved ejection fraction.

Hypoglycaemia: Abnormally low blood glucose.

Incretin: A gut-derived hormone that strengthens the insulin response to nutrients.

Insulin: A pancreatic hormone that helps glucose move from the blood into cells.

MASH: Metabolic dysfunction-associated steatohepatitis, a progressive inflammatory form of metabolic liver disease.

Obstructive sleep apnoea: Repeated narrowing or closure of the upper airway during sleep.

Peptide: A chain of amino acids that may function as a hormone, signalling molecule or medicine.

Prediabetes: Blood-glucose levels above the usual range but below the diagnostic threshold for type 2 diabetes.

Receptor: A cellular structure that responds to a particular chemical signal.

Satiety: The feeling of fullness that reduces the desire to continue eating.

Type 2 diabetes: A metabolic condition involving impaired insulin action, insufficient insulin secretion or both.

This article is provided for general scientific and educational purposes.

It is not intended to diagnose, treat or prevent any medical condition, and it should not be interpreted as personal medical advice, prescribing guidance or instructions for using any medicine.

TZ GLP1 is a prescription-only medicine. Treatment decisions should be made with an appropriately qualified healthcare professional who can consider a person’s medical history, other medicines, treatment goals and individual risks